Urogenital Atrophy Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Urogenital Atrophy. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Urogenital Atrophy Indian Medical PG Question 1: The established benefits of estrogen replacement therapy in menopausal women include a reduction in all of the following EXCEPT
- A. Hot flushes
- B. Mood depression (Correct Answer)
- C. Atrophic vaginitis
- D. Osteoporosis
Urogenital Atrophy Explanation: ***Mood depression*** - While some women may experience mood changes during menopause, estrogen replacement therapy does not consistently or significantly reduce **mood depression**. - The relationship between estrogen and mood is complex, and depression in menopausal women often has **multifactorial causes** beyond hormonal changes. *Hot flushes* - Estrogen replacement therapy is highly effective in alleviating **vasomotor symptoms** such as hot flushes and night sweats [1, 2]. - These symptoms are directly linked to declining estrogen levels. *Atrophic vaginitis* - Estrogen therapy effectively treats **genitourinary syndrome of menopause** (GSM), including symptoms of atrophic vaginitis. - It restores the **vaginal epithelium**, increasing lubrication and reducing dryness, itching, and dyspareunia. *Osteoporosis* - Estrogen plays a crucial role in **bone density maintenance** and its decline at menopause contributes to accelerated bone loss. - Estrogen replacement therapy is a known treatment to prevent and manage **postmenopausal osteoporosis** by reducing bone turnover [1].
Urogenital Atrophy Indian Medical PG Question 2: Which condition is most commonly associated with female sexual dysfunction characterized by painful intercourse?
- A. Absence of ovary
- B. Vaginismus (Correct Answer)
- C. Gonadal dysgenesis
- D. Intersex condition
Urogenital Atrophy Explanation: ***Vaginismus***
- **Vaginismus** is a condition characterized by involuntary spasms of the muscles surrounding the vaginal opening, leading to painful intercourse (**dyspareunia**) or inability to complete penetration.
- It's a common cause of female sexual dysfunction where the primary symptom is **pain or difficulty with vaginal penetration**.
*Absence of ovary*
- The **absence of ovaries** primarily affects hormone production and fertility but does not directly cause involuntary vaginal muscle spasms leading to painful intercourse.
- While it can lead to vaginal atrophy due to lack of estrogen, which might cause painful intercourse, it's not the most direct or common cause of the specific dysfunction described.
*Gonadal dysgenesis*
- **Gonadal dysgenesis** refers to abnormal development of the gonads, often leading to hormonal imbalances and infertility.
- This condition is not typically associated with muscle spasms causing painful intercourse; its main manifestations are related to sexual development and endocrine function.
*Intersex condition*
- An **intersex condition** involves atypical development of internal and external sexual anatomy.
- While intersex conditions can lead to a variety of sexual health issues, they do not inherently or most commonly present with the involuntary vaginal muscular spasms characteristic of vaginismus.
Urogenital Atrophy Indian Medical PG Question 3: A postmenopausal diabetic woman presents with bleeding per vaginum. The most likely diagnosis is :
- A. Malignancy of the vulva
- B. Malignancy of the cervix
- C. Malignancy of the endometrium (Correct Answer)
- D. Malignancy of the ovary
Urogenital Atrophy Explanation: ***Malignancy of the endometrium***
- **Postmenopausal bleeding** is the classic presenting symptom of **endometrial cancer**, which must be ruled out in all such cases.
- **Diabetes** is a known risk factor for endometrial cancer, along with obesity, hypertension, and unopposed estrogen exposure.
*Malignancy of the vulva*
- Vulvar cancer typically presents with a **pruritic lesion**, lump, or ulcer on the vulva, rather than solely with vaginal bleeding.
- While bleeding can occur from an advanced vulvar lesion, it is not the primary or most common presentation for new onset postmenopausal bleeding.
*Malignancy of the cervix*
- Cervical cancer often presents with **postcoital bleeding** or irregular vaginal bleeding in premenopausal women, or less commonly, postmenopausal bleeding.
- Screening with **Pap smears** typically detects precancerous changes or early cervical cancer, making it less likely to be the first presentation with postmenopausal bleeding in a well-screened population.
*Malignancy of the ovary*
- Ovarian cancer is often asymptomatic in its early stages and presents with non-specific symptoms like **abdominal distension**, bloating, or pelvic pain.
- **Vaginal bleeding** is not a typical symptom of ovarian cancer, unless the tumor is very large, involves adjacent structures, or is a hormone-producing tumor.
Urogenital Atrophy Indian Medical PG Question 4: Most common anomaly of upper urogenital tract is -
- A. Uretero pelvic junction stenosis (Correct Answer)
- B. Ureterocele
- C. Ectopic ureter
- D. Ectopic urethral opening
Urogenital Atrophy Explanation: ***Uretero pelvic junction stenosis***
- **Ureteropelvic junction (UPJ) obstruction** is the most common cause of **antenatally detected hydronephrosis**, making it the most frequent anomaly of the upper urogenital tract.
- It results from an intrinsic or extrinsic narrowing at the junction of the **renal pelvis** and the **ureter**, impeding urine flow.
*Ectopic urethral opening*
- This anomaly involves the **urethral opening** being in an abnormal location, such as **hypospadias** or **epispadias** in males, or into the vagina in females.
- While relatively common, it is an anomaly of the **lower urogenital tract**, specifically the urethra, not the upper tract.
*Ureterocele*
- A ureterocele is a **cystic dilation** of the distal part of the ureter as it enters the bladder.
- While it can be associated with varying degrees of **upper tract obstruction**, it is not as common as UPJ stenosis.
*Ectopic ureter*
- An ectopic ureter involves a ureter that drains into an abnormal location other than the **trigone of the bladder**.
- This condition is less common than UPJ stenosis and is often associated with a **duplex collecting system**.
Urogenital Atrophy Indian Medical PG Question 5: Earliest menopausal symptom is :
- A. Vaginal discharge
- B. Osteoporosis
- C. Hot flushes (Correct Answer)
- D. Spotting
Urogenital Atrophy Explanation: ***Hot flushes***
- **Hot flushes** are the **earliest and most common vasomotor symptom** experienced by women during perimenopause due to fluctuating estrogen levels.
- They are often the first **symptomatic complaint** that brings women to clinical attention and can begin several years before the final menstrual period.
- While menstrual irregularities occur concurrently, hot flushes are considered the hallmark **early symptom** of menopausal transition.
*Vaginal discharge*
- **Vaginal discharge** can occur due to various reasons, including infections or hormonal changes, but it is not typically the earliest or a universal symptom of menopause.
- While vaginal dryness and atrophy are common menopausal symptoms, increased discharge is not characteristic of early menopause.
*Osteoporosis*
- **Osteoporosis** is a long-term consequence of estrogen deficiency that develops **years after menopause**, leading to decreased bone density.
- It is not an early symptom but rather a chronic condition that manifests significantly later in the postmenopausal period.
*Spotting*
- **Spotting** (intermenstrual bleeding) can be a sign of perimenopause as menstrual cycles become irregular.
- While **menstrual irregularity** is an early feature of perimenopause, hot flushes are more consistently recognized as the **earliest symptomatic presentation** that characterizes the menopausal transition.
Urogenital Atrophy Indian Medical PG Question 6: What is the management for women with polycystic ovary syndrome (PCOS) and hirsutism?
- A. Ethinyl estradiol + Cyproterone Acetate (Correct Answer)
- B. Ethinyl estradiol
- C. Levonorgestrel
- D. Ethinyl estradiol + Levonorgestrel
Urogenital Atrophy Explanation: ***Ethinyl estradiol + Cyproterone Acetate***
- This combination is effective for managing **hirsutism** in PCOS because ethinyl estradiol suppresses **gonadotropins** and ovarian androgen production, while **cyproterone acetate** is a potent **anti-androgen** that blocks androgen effects at the receptor level.
- The anti-androgenic properties of cyproterone acetate directly address the excess androgen activity responsible for hirsutism.
*Ethinyl estradiol*
- While ethinyl estradiol (an estrogen) can suppress **gonadotropins** and thus reduce ovarian androgen production, it alone is not primarily effective in directly addressing and reversing existing hirsutism.
- It would not sufficiently counteract the effects of high androgens on hair follicles without an additional anti-androgen.
*Levonorgestrel*
- Levonorgestrel is a **progestin** with **androgenic properties**, particularly at higher doses.
- This would potentially worsen hirsutism rather than improve it, as it contributes to androgenic effects.
*Ethinyl estradiol + Levonorgestrel*
- This combination is a common component of oral contraceptive pills, but **levonorgestrel** has some **androgenic activity**, which means it could worsen or fail to improve hirsutism.
- While ethinyl estradiol lowers androgens, the mild androgenic effect of levonorgestrel might counteract the desired anti-androgenic effect needed to treat hirsutism effectively.
Urogenital Atrophy Indian Medical PG Question 7: A 60-year-old woman comes with 3rd degree uterine prolapse. What will be the management?
- A. Vaginal hysterectomy with pelvic floor repair (Correct Answer)
- B. Pelvic floor repair
- C. Sacrospinous fixation
- D. Pessary
Urogenital Atrophy Explanation: ***Vaginal hysterectomy with pelvic floor repair***
- A **3rd degree uterine prolapse** means the cervix and uterus protrude beyond the introitus, requiring surgical intervention in most cases.
- **Vaginal hysterectomy** addresses the prolapsed uterus, and **pelvic floor repair** (e.g., anterior/posterior colporrhaphy) simultaneously reinforces weakened pelvic support structures to prevent recurrence.
- This is the **most definitive surgical management** for complete uterine prolapse in a postmenopausal woman.
*Pelvic floor repair*
- While important for addressing fascial defects, **pelvic floor repair alone** is insufficient for 3rd-degree uterine prolapse where the uterus itself is significantly descended.
- This option would leave the **prolapsed uterus** unaddressed, making long-term surgical success unlikely.
*Sacrospinous fixation*
- **Sacrospinous fixation** is a procedure primarily used for **vaginal vault prolapse** (post-hysterectomy) or as part of apical suspension, by attaching the vaginal apex to the sacrospinous ligament.
- While it can be used for **uterine-sparing procedures** (sacrospinous hysteropexy), it is not the primary or sole management when the standard approach is vaginal hysterectomy with repair.
*Pessary*
- A **pessary** is a non-surgical option appropriate for patients who are **not surgical candidates** (significant comorbidities, elderly frail patients) or those who **decline surgery**.
- While it can provide symptomatic relief even for 3rd-degree prolapse, it requires regular follow-up and is generally considered a **conservative/temporizing measure** rather than definitive management when surgery is feasible.
Urogenital Atrophy Indian Medical PG Question 8: Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except
- A. Vaginal atrophy
- B. Osteoporosis
- C. Vasomotor symptoms
- D. Prevention of CAD (Correct Answer)
Urogenital Atrophy Explanation: ***Prevention of CAD***
- While HRT was initially thought to be cardioprotective, large-scale studies like the **Women's Health Initiative (WHI)** demonstrated that it does **not prevent coronary artery disease (CAD)** and may even increase the risk of cardiovascular events, especially in older postmenopausal women or those initiating therapy years after menopause.
- The potential benefits regarding CAD prevention are outweighed by risks such as **stroke** and **venous thromboembolism**.
*Vaginal atrophy*
- **Estrogen deficiency** in postmenopausal women leads to thinning, dryness, and inflammation of the vaginal walls, causing symptoms like dryness, irritation, and painful intercourse.
- **Local or systemic estrogen therapy** effectively reverses these changes by restoring vaginal tissue health.
*Osteoporosis*
- **Bone loss** accelerates after menopause due to declining estrogen levels, increasing the risk of osteoporosis and fractures.
- HRT, particularly estrogen, is effective in **preventing and treating osteoporosis** by inhibiting bone resorption and preserving bone mineral density.
*Vasomotor symptoms*
- **Hot flashes** and **night sweats** are common and often debilitating symptoms of menopause, directly linked to fluctuating and declining estrogen levels.
- HRT, especially systemic estrogen, is the **most effective treatment** for alleviating these symptoms by stabilizing thermoregulatory control.
Urogenital Atrophy Indian Medical PG Question 9: Which of the following statements about the benefits of hormone replacement therapy is incorrect?
- A. Reduction in colorectal cancer (20%) (Correct Answer)
- B. Improvement in urogenital atrophy
- C. Increase in bone mineral density (2-5%)
- D. 40 - 50% improvement in vasomotor symptoms
Urogenital Atrophy Explanation: ***Reduction in colorectal cancer (20%)***
- While the **Women's Health Initiative (WHI)** study demonstrated a reduction in colorectal cancer incidence with combined estrogen-progestin therapy, this is **NOT considered an established or recommended benefit** of HRT.
- The evidence is **inconsistent** across different studies, and importantly, colorectal cancers detected in HRT users were found at **more advanced stages**.
- The **risks of HRT** (increased breast cancer, cardiovascular events, venous thromboembolism) significantly **outweigh** this uncertain benefit.
- This is **NOT listed as an indication** for HRT in clinical guidelines, making this statement misleading when discussing "benefits" of HRT.
*Improvement in urogenital atrophy*
- **Estrogen deficiency** during menopause causes **vaginal and urethral atrophy**, leading to **dyspareunia, vaginal dryness, urgency**, and **recurrent UTIs**.
- **Estrogen replacement therapy** (especially local vaginal estrogen) is **highly effective** in reversing urogenital atrophy.
- This is a **well-established, FDA-approved indication** for HRT.
*Increase in bone mineral density (2-5%)*
- **Estrogen inhibits osteoclast activity** and promotes bone formation, playing a crucial role in maintaining **bone mineral density**.
- HRT produces a **significant increase in BMD (2-5%)**, helping to **prevent osteoporosis** and reduce fracture risk in postmenopausal women.
- This is a **proven benefit** and approved indication for HRT, particularly for women at high risk of osteoporosis.
*40-50% improvement in vasomotor symptoms*
- **Vasomotor symptoms** (hot flashes and night sweats) are the **hallmark of menopause**, caused by **estrogen deficiency**.
- **HRT is the most effective treatment**, reducing frequency and severity by **40-50%** or more.
- This is the **primary and most important indication** for initiating HRT in symptomatic menopausal women.
Urogenital Atrophy Indian Medical PG Question 10: Senile vaginitis is due to :
- A. Diabetes
- B. Gonococcal infection
- C. Oestrogen deficiency (Correct Answer)
- D. Cancer cervix
Urogenital Atrophy Explanation: ***Oestrogen deficiency***
- **Senile vaginitis**, also known as **atrophic vaginitis**, is primarily caused by **decreased oestrogen levels**, particularly after menopause.
- Reduced oestrogen leads to thinning and drying of the vaginal walls, making them more susceptible to inflammation and infection.
*Diabetes*
- While uncontrolled **diabetes** can increase the risk of vaginal infections, such as **candidiasis**, it is not the direct cause of senile vaginitis itself.
- Diabetic neuropathy can affect vaginal sensation, but does not cause the atrophic changes observed in senile vaginitis.
*Gonococcal infection*
- **Gonococcal infection** is a sexually transmitted infection that causes acute inflammation of the mucous membranes, but not the long-term atrophic changes seen in senile vaginitis.
- It would present with purulent discharge and dysuria, which are distinct from the symptoms of senile vaginitis.
*Cancer cervix*
- **Cervical cancer** is a malignancy of the cervix and does not directly cause senile vaginitis.
- While it can manifest with abnormal vaginal bleeding or discharge, these symptoms are typically due to the tumor itself and not the atrophic changes characteristic of senile vaginitis.
More Urogenital Atrophy Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
oka
